{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:36:23Z","timestamp":1765280183554,"version":"3.46.0"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0030_s_001_w2aab3b7b6b1b6b1aab1c14b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An effective treatment strategy for peritoneal metastasis (PM) of hepatocellular carcinoma (HCC-PM) has yet to be established. Although cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown favorable outcomes in certain malignancies, their role in peritoneal metastatic HCC is unclear. Herein, we present a series of patients with HCC-PM treated with CRS\/HIPEC and evaluate their outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0030_s_002_w2aab3b7b6b1b6b1aab1c14b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Records of patients with HCC-PM who had undergone CRS\/HIPEC at the Hyperthermia Center of Yuan\u2019s General Hospital, Kaohsiung, Taiwan, between September 2015 and December 2016 were reviewed retrospectively. Patients were followed up until September 2019. We assessed the clinical courses and outcomes of these patients to clarify the benefits of CRS\/HIPEC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0030_s_003_w2aab3b7b6b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six patients were included in our study. HCC-PM occurred synchronously in one patient and occurred metachronously in five patients after therapeutic minimally invasive procedures, including radiofrequency ablation, laparoscopic hepatectomy, robotic hepatectomy or spontaneously. The median peritoneal cancer index was 18.5. All patients experienced complete peritoneal cytoreduction without perioperative mortality. One patient had two CTCAE grade 3 complications. The median follow-up was 16\u2006months. The median overall survival was 15.7\u2006months. Four patients died of lung metastasis or liver failure owing to intrahepatic recurrence. The survival rates observed at 1, 2, and 4\u2006years were 66.7%, 33.3%, and 33.3%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0030_s_004a_w2aab3b7b6b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CRS followed by HIPEC is feasible in patients with HCC-PM and might provide selected patients a chance for local disease control and longer survival. CRS\/HIPEC might be considered as a treatment option in highly selected patients, as part of multimodal therapy approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0030","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T11:49:10Z","timestamp":1590493750000},"source":"Crossref","is-referenced-by-count":7,"title":["Cytoreduction surgery and hyperthermic intraperitoneal chemotherapy for treating advanced peritoneal metastases of hepatocellular carcinoma"],"prefix":"10.1515","volume":"5","author":[{"given":"Kuo-Chen","family":"Hung","sequence":"first","affiliation":[{"name":"Department of Trauma Surgery, Kaohsiung Chang Gung Memorial Hospital , Chang Gung University and College of Medicine , Kaohsiung 83301 , Taiwan"},{"name":"Hyperthermic Center, Department of Surgery , Yuan\u2019s General Hospital , Kaohsiung 802793 , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Animal Science , National Peimen Agriculture and Industrial school , Tainan , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guan-Cheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Hemato-oncology, Department of Internal Medicine , Yuan\u2019s General Hospital , Kaohsiung , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Fu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Education and Research , Yuan\u2019s General Hospital , Kaohsiung , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Teng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biological Science and Technology , Chung Hwa University of Medical Technology , Tainan , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-2949","authenticated-orcid":false,"given":"Chia-Chang","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, National Cheng Kung University Hospital , College of Medicine, National Cheng Kung University , Tainan , Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"key":"2025120909253178174_j_pp-2019-0030_ref_001_w2aab3b7b6b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359\u201386. Epub 2014\/ 09\/16. DOI:10.1002\/ijc.29210. PubMed PMID: 25220842.","DOI":"10.1002\/ijc.29210"},{"key":"2025120909253178174_j_pp-2019-0030_ref_002_w2aab3b7b6b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 2016;46:372\u201390. Epub 2016\/ 03\/13. DOI:10.1111\/hepr.12697. PubMed PMID: 26970231.","DOI":"10.1111\/hepr.12697"},{"key":"2025120909253178174_j_pp-2019-0030_ref_003_w2aab3b7b6b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Lin CC, Liang HP, Lee HS, Huang GT, Yang PM, Ho MC, et al. Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. J Gastroenterol Hepatol 2009;24:815\u201320. DOI:10.1111\/j.1440-1746.2009.05848.x. PMID: 19655437.","DOI":"10.1111\/j.1440-1746.2009.05848.x"},{"key":"2025120909253178174_j_pp-2019-0030_ref_004_w2aab3b7b6b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Kow AW, Kwon CH, Song S, Kim JM, Joh JW. Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma in a tertiary institution. Surgery 2015;157:645\u201353. Epub 2015\/03\/22. DOI:10.1016\/j.surg.2014.07.024. PubMed PMID: 25794626.","DOI":"10.1016\/j.surg.2014.07.024"},{"key":"2025120909253178174_j_pp-2019-0030_ref_005_w2aab3b7b6b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Hashimoto M, Sasaki K, Moriyama J, Matsuda M, Watanabe G. Resection of peritoneal metastases in patients with hepatocellular carcinoma. Surgery 2013;153:727\u201331. Epub 2012\/ 06\/19. DOI:10.1016\/j.surg.2012.03.031. PubMed PMID: 22705249.","DOI":"10.1016\/j.surg.2012.03.031"},{"key":"2025120909253178174_j_pp-2019-0030_ref_006_w2aab3b7b6b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Yeh CN, Chen MF. Resection of peritoneal implantation of hepatocellular carcinoma after hepatic resection: risk factors and prognostic analysis. World J Surg 2004;28:382\u20136. Epub 2004\/ 03\/03. DOI:10.1007\/s00268-003-7319-7. PubMed PMID: 14994148.","DOI":"10.1007\/s00268-003-7319-7"},{"key":"2025120909253178174_j_pp-2019-0030_ref_007_w2aab3b7b6b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 2009;27:6237\u201342. Epub 2009\/ 11\/18. DOI:10.1200\/jco.2009.23.9640. PubMed PMID: 19917862.","DOI":"10.1200\/JCO.2009.23.9640"},{"key":"2025120909253178174_j_pp-2019-0030_ref_008_w2aab3b7b6b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219\u201328. Epub 2004\/ 03\/31. DOI:10.1016\/s1470-2045(04)01425-1. PubMed PMID: 15050953.","DOI":"10.1016\/S1470-2045(04)01425-1"},{"key":"2025120909253178174_j_pp-2019-0030_ref_009_w2aab3b7b6b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727\u201331. Epub 2000\/ 01\/06. DOI:10.1007\/s10434-999-0727-7. PubMed PMID: 10622499.","DOI":"10.1007\/s10434-999-0727-7"},{"key":"2025120909253178174_j_pp-2019-0030_ref_010_w2aab3b7b6b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374. Epub 1996\/01\/01. DOI:10.1007\/978-1-4613-1247-5_23. PubMed PMID: 8849962.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909253178174_j_pp-2019-0030_ref_011_w2aab3b7b6b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008;15:2426\u201332. Epub 2008\/ 06\/04. DOI:10.1245\/s10434-008-9966-2. PubMed PMID: 18521686.","DOI":"10.1245\/s10434-008-9966-2"},{"key":"2025120909253178174_j_pp-2019-0030_ref_012_w2aab3b7b6b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Yamada R, Bassaco B, Bracewell S, Gillen K, Kocher M, Collins H, et al. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). J Gastrointest Oncol 2019;10:348\u201353. DOI:10.21037\/jgo.2019.01.01. PMID:31032104.","DOI":"10.21037\/jgo.2019.01.01"},{"key":"2025120909253178174_j_pp-2019-0030_ref_013_w2aab3b7b6b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Miller TP, Fisher BT, Getz KD, Sack L, Razzaghi H, Seif AE, et al. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatr Blood Cancer 2019;66:e27747. Epub 2019\/04\/11. DOI:10.1002\/pbc.27747. PubMed PMID: 30968531; PubMed Central PMCID: PMCPMC6681806.","DOI":"10.1002\/pbc.27747"},{"key":"2025120909253178174_j_pp-2019-0030_ref_014_w2aab3b7b6b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Tabrizian P, Franssen B, Jibara G, Sweeney R, Sarpel U, Schwartz M, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma. J Surg Oncol 2014;110:786\u201390. Epub 2014\/08\/06. DOI:10.1002\/jso.23739. PubMed PMID: 25091997.","DOI":"10.1002\/jso.23739"},{"key":"2025120909253178174_j_pp-2019-0030_ref_015_w2aab3b7b6b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, JL R, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182\u2013236. Epub 2018\/ 04\/10. DOI:10.1016\/j.jhep.2018.03.019. PubMed PMID: 29628281.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"2025120909253178174_j_pp-2019-0030_ref_016_w2aab3b7b6b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25\u201334. Epub 2008\/ 12\/20. DOI:10.1016\/s1470-2045(08)70285-7. PubMed PMID: 19095497.","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"2025120909253178174_j_pp-2019-0030_ref_017_w2aab3b7b6b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163\u201373. Epub 2018\/ 02\/13. DOI:10.1016\/s0140-6736(18)30207-1. PubMed PMID: 29433850.","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"2025120909253178174_j_pp-2019-0030_ref_018_w2aab3b7b6b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56\u201366. Epub 2016\/ 12\/10. DOI:10.1016\/s0140-6736(16)32453-9. PubMed PMID: 27932229.","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"2025120909253178174_j_pp-2019-0030_ref_019_w2aab3b7b6b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018;379:54\u201363. Epub 2018\/07\/05. DOI:10.1056\/NEJMoa1717002. PubMed PMID: 29972759.","DOI":"10.1056\/NEJMoa1717002"},{"key":"2025120909253178174_j_pp-2019-0030_ref_020_w2aab3b7b6b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Ding JH, Chua TC, Al-Mohaimeed K, Morris DL. Hepatocellular carcinoma peritoneal metastases: report of three cases and collective review of the literature. Ann Acad Med Singapore 2010;39:734\u20134. Epub 2010\/ 10\/20.PubMed PMID: 20957309.","DOI":"10.47102\/annals-acadmedsg.V39N9p734"},{"key":"2025120909253178174_j_pp-2019-0030_ref_021_w2aab3b7b6b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254\u201361. Epub 1998\/ 04\/21. DOI:10.1002\/(sici)1098-2388(199804\/05)14:3<254::aid-ssu10>3.0.co;2-u. PubMed PMID: 9548609.","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<254::AID-SSU10>3.0.CO;2-U"},{"key":"2025120909253178174_j_pp-2019-0030_ref_022_w2aab3b7b6b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012;30:2449\u201356. Epub 2012\/ 05\/23. DOI:10.1200\/jco.2011.39.7166. PubMed PMID: 22614976.","DOI":"10.1200\/JCO.2011.39.7166"},{"key":"2025120909253178174_j_pp-2019-0030_ref_023_w2aab3b7b6b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737\u201343. Epub 2003\/10\/11. DOI:10.1200\/jco.2003.04.187. PubMed PMID: 14551293.","DOI":"10.1200\/JCO.2003.04.187"},{"key":"2025120909253178174_j_pp-2019-0030_ref_024_w2aab3b7b6b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27:681\u20135. Epub 2008\/ 12\/24. DOI:10.1200\/jco.2008.19.7160. PubMed PMID: 19103728.","DOI":"10.1200\/JCO.2008.19.7160"},{"key":"2025120909253178174_j_pp-2019-0030_ref_025_w2aab3b7b6b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Quenet F, Elias D, Roca L, Goere D, Ghouti L, Pocard M, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol 2018;36:abstr LBA3503.","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503"},{"key":"2025120909253178174_j_pp-2019-0030_ref_026_w2aab3b7b6b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"K\u00f6nigsrainer A, Rau B. Cytoreductive Surgery (CRS) and HIPEC: don\u2019t throw the baby out with the bathwater. Pleura Peritoneum 2018;3:20180131. DOI:10.1515\/pp-2018-0131.","DOI":"10.1515\/pp-2018-0131"},{"key":"2025120909253178174_j_pp-2019-0030_ref_027_w2aab3b7b6b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008;113:315\u201325. Epub 2008\/05\/14. DOI:10.1002\/cncr.23553. PubMed PMID: 18473354.","DOI":"10.1002\/cncr.23553"},{"key":"2025120909253178174_j_pp-2019-0030_ref_028_w2aab3b7b6b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Helm CW. Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am 2012;21:645\u201363. Epub 2012\/10\/02. DOI:10.1016\/j.soc.2012.07.007. PubMed PMID: 23021722.","DOI":"10.1016\/j.soc.2012.07.007"},{"key":"2025120909253178174_j_pp-2019-0030_ref_029_w2aab3b7b6b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Chang SJ, Bristow RE, Ryu HS. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012;19:4059\u201367. Epub 2012\/07\/07. DOI:10.1245\/s10434-012-2446-8. PubMed PMID: 22766983.","DOI":"10.1245\/s10434-012-2446-8"},{"key":"2025120909253178174_j_pp-2019-0030_ref_030_w2aab3b7b6b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909253178174_j_pp-2019-0030_ref_031_w2aab3b7b6b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005;92:370\u20135. Epub 2005\/03\/02. DOI:10.1002\/bjs.4695. PubMed PMID: 15739249.","DOI":"10.1002\/bjs.4695"},{"key":"2025120909253178174_j_pp-2019-0030_ref_032_w2aab3b7b6b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010;17:2370\u20137. Epub 2010\/03\/26. DOI:10.1245\/s10434-010-1039-7. PubMed PMID: 20336386.","DOI":"10.1245\/s10434-010-1039-7"},{"key":"2025120909253178174_j_pp-2019-0030_ref_033_w2aab3b7b6b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol 2019;37:2028\u201340. Epub 2019\/05\/14. DOI:10.1200\/JCO.18.01688. PubMed PMID: 31084544.","DOI":"10.1200\/JCO.18.01688"},{"key":"2025120909253178174_j_pp-2019-0030_ref_034_w2aab3b7b6b1b6b1ab2b2c34Aa","doi-asserted-by":"crossref","unstructured":"Ji ZH, An SL, Li XB, Liu G, Li Y. Long-term progression-free survival of hepatocellular carcinoma with synchronous diffuse peritoneal metastasis treated by CRS+HIPEC: A case report and literature review. Medicine (Baltimore) 2019;98:e14628. Epub 2019\/ 03\/01. DOI:10.1097\/md.0000000000014628. PubMed PMID: 30813197; PubMed Central PMCID: PMCPMC6408117.","DOI":"10.1097\/MD.0000000000014628"},{"key":"2025120909253178174_j_pp-2019-0030_ref_035_w2aab3b7b6b1b6b1ab2b2c35Aa","doi-asserted-by":"crossref","unstructured":"Mehta S, Schwarz L, Spiliotis J, Hsieh MC, Akaishi EH, Goere D, et al. Is there an oncological interest in the combination of CRS\/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. Eur J Surg Oncol 2018;44:1786\u201392. Epub 2018\/ 06\/11. DOI:10.1016\/j.ejso.2018.05.021. PubMed PMID: 29885982.","DOI":"10.1016\/j.ejso.2018.05.021"},{"key":"2025120909253178174_j_pp-2019-0030_ref_036_w2aab3b7b6b1b6b1ab2b2c36Aa","doi-asserted-by":"crossref","unstructured":"Berger Y, Spivack JH, Heskel M, Aycart SN, Labow DM, Sarpel U. Extrahepatic metastasectomy for hepatocellular carcinoma: predictors of long-term survival. J Surg Oncol 2016;114:469\u201374. Epub 2016\/ 06\/24. DOI:10.1002\/jso.24340. PubMed PMID: 27334650.","DOI":"10.1002\/jso.24340"},{"key":"2025120909253178174_j_pp-2019-0030_ref_037_w2aab3b7b6b1b6b1ab2b2c37Aa","unstructured":"Spiliotis J, Nikolaou G, Kopanakis N, Vassiliadou D, Terra A, Efstathiou E. Hepatocellular carcinoma peritoneal metastasis: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Gulf J Oncolog 2017;1:20\u20133. Epub 2017\/08\/12.PubMed PMID: 28797997."},{"key":"2025120909253178174_j_pp-2019-0030_ref_038_w2aab3b7b6b1b6b1ab2b2c38Aa","doi-asserted-by":"crossref","unstructured":"Esquivel J, Elias D, Baratti D, Kusamura S, Deraco M. Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol 2008;98:263\u20137. Epub 2008\/08\/30. DOI:10.1002\/jso.21053. PubMed PMID: 18726889.","DOI":"10.1002\/jso.21053"},{"key":"2025120909253178174_j_pp-2019-0030_ref_039_w2aab3b7b6b1b6b1ab2b2c39Aa","doi-asserted-by":"crossref","unstructured":"Bakrin N, Bereder JM, Decullier E, Classe JM, Msika S, Lorimier G, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013;39:1435\u201343. Epub 2013\/11\/12. DOI:10.1016\/j.ejso.2013.09.030. PubMed PMID: 24209430.","DOI":"10.1016\/j.ejso.2013.09.030"},{"key":"2025120909253178174_j_pp-2019-0030_ref_040_w2aab3b7b6b1b6b1ab2b2c40Aa","doi-asserted-by":"crossref","unstructured":"Stewart JH, 4th, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol 2005;12:765\u201377. Epub 2005\/ 09\/01. DOI:10.1245\/aso.2005.12.001. PubMed PMID: 16132375.","DOI":"10.1245\/ASO.2005.12.001"},{"key":"2025120909253178174_j_pp-2019-0030_ref_041_w2aab3b7b6b1b6b1ab2b2c41Aa","doi-asserted-by":"crossref","unstructured":"Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124\u20139. Epub 2001\/05\/09. DOI:10.1053\/jhep.2001.24233. PubMed PMID: 11343240.","DOI":"10.1053\/jhep.2001.24233"},{"key":"2025120909253178174_j_pp-2019-0030_ref_042_w2aab3b7b6b1b6b1ab2b2c42Aa","doi-asserted-by":"crossref","unstructured":"Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437\u201347. Epub 2007\/ 05\/22. DOI:10.1016\/j.ctrv.2007.04.001. PubMed PMID: 17512669.","DOI":"10.1016\/j.ctrv.2007.04.001"},{"key":"2025120909253178174_j_pp-2019-0030_ref_043_w2aab3b7b6b1b6b1ab2b2c43Aa","doi-asserted-by":"crossref","unstructured":"Cho JY, Han HS, Wakabayashi G, Soubrane O, Geller D, O\u2019Rourke N, et al. Practical guidelines for performing laparoscopic liver resection based on the second international laparoscopic liver consensus conference. Surg Oncol 2018;27:A5\u2013a9. Epub 2018\/01\/18. DOI:10.1016\/j.suronc.2017.12.003. PubMed PMID: 29338984.","DOI":"10.1016\/j.suronc.2017.12.003"},{"key":"2025120909253178174_j_pp-2019-0030_ref_044_w2aab3b7b6b1b6b1ab2b2c44Aa","doi-asserted-by":"crossref","unstructured":"Liu R, Wakabayashi G, Kim HJ, Choi GH, Yiengpruksawan A, Fong Y, et al. International consensus statement on robotic hepatectomy surgery in 2018. World J Gastroenterol 2019;25:1432\u201344. Epub 2019\/04\/06. DOI:10.3748\/wjg.v25.i12.1432. PubMed PMID: 30948907; PubMed Central PMCID: PMCPMC6441912.","DOI":"10.3748\/wjg.v25.i12.1432"},{"key":"2025120909253178174_j_pp-2019-0030_ref_045_w2aab3b7b6b1b6b1ab2b2c45Aa","doi-asserted-by":"crossref","unstructured":"Maarschalk J, Robinson SM, White SA. Port site metastases following laparoscopic liver resection for hepatocellular carcinoma. Ann R Coll Surg Engl 2015;97:e52\u20133. Epub 2015\/10\/22. DOI:10.1308\/003588414x14055925060910. PubMed PMID: 26488054; PubMed Central PMCID: PMCPMC4473883.","DOI":"10.1308\/003588414X14055925060910"},{"key":"2025120909253178174_j_pp-2019-0030_ref_046_w2aab3b7b6b1b6b1ab2b2c46Aa","doi-asserted-by":"crossref","unstructured":"Kihara K, Endo K, Suzuki K, Nakamura S, Sawata T, Shimizu T, et al. Isolated port-site metastasis of hepatocellular carcinoma after laparoscopic liver resection. Asian J Endosc Surg 2017;10:191\u20133. Epub 2016\/ 10\/18. DOI:10.1111\/ases.12339. PubMed PMID: 27748057.","DOI":"10.1111\/ases.12339"},{"key":"2025120909253178174_j_pp-2019-0030_ref_047_w2aab3b7b6b1b6b1ab2b2c47Aa","doi-asserted-by":"crossref","unstructured":"Yang Z, Liu X, Tan H, Liu L. Lymphovascular tumor embolus might be a risk factor for peritoneal metastasis after laparoscopic hepatectomy for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2018;7:503\u20134. Epub 2019\/ 01\/18. DOI:10.21037\/hbsn.2018.07.04. PubMed PMID: 30652102; PubMed Central PMCID: PMCPMC6295386.","DOI":"10.21037\/hbsn.2018.07.04"}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/5\/2\/article-20190030.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0030\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0030\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:05:05Z","timestamp":1765278305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0030\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,5,15]]},"published-print":{"date-parts":[[2020,5,26]]}},"alternative-id":["10.1515\/pp-2019-0030"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0030","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"type":"electronic","value":"2364-768X"},{"type":"print","value":"2364-7671"}],"subject":[],"published":{"date-parts":[[2020,5,15]]},"article-number":"20190030"}}